Phreesia, Inc. (NYSE:PHR) Stock Has Consensus Target Price of $14.07 According to Analysts

Phreesia, Inc. (NYSE:PHR) has been given an average rating of “Hold” by the nineteen research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $14.07.

Several equities research analysts recently commented on PHR shares. Canaccord Genuity Group reissued a “buy” rating and issued a $16.00 price target on shares of Phreesia in a research note on Thursday, September 3rd. Citigroup reaffirmed a “market perform” rating on shares of Phreesia in a research note on Tuesday, October 20th. Needham & Company LLC restated a “buy” rating and issued a $14.00 price objective on shares of Phreesia in a research note on Monday, August 31st. Barclays lifted their target price on shares of Phreesia from $10.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. Finally, Raymond James Financial lowered shares of Phreesia from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 8th.

Phreesia Price Performance

PHR opened at $12.44 on Wednesday. The firm has a market cap of $772.16 million, a price-to-earnings ratio of 73.18 and a beta of 0.84. The company’s 50-day moving average price is $11.05 and its 200 day moving average price is $10.99. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.33. Phreesia has a fifty-two week low of $7.77 and a fifty-two week high of $23.78.

Phreesia (NYSE:PHR) last released its earnings results on Wednesday, September 2nd. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.06). The company had revenue of $129.46 million for the quarter, compared to analyst estimates of $129.06 million. Phreesia had a net margin of 2.06% and a return on equity of 5.22%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.01 EPS. As a group, sell-side analysts expect that Phreesia will post 0.33 earnings per share for the current year.

Insider Transactions at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 6,662 shares of Phreesia stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $10.08, for a total value of $67,152.96. Following the transaction, the general counsel directly owned 266,574 shares of the company’s stock, valued at $2,687,065.92. The trade was a 2.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Phreesia

Several hedge funds have recently made changes to their positions in the stock. Pale Fire Capital SE bought a new position in Phreesia in the first quarter worth $72,481,000. BlackRock Inc. acquired a new position in shares of Phreesia in the 2nd quarter valued at $72,234,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Phreesia during the 2nd quarter worth about $6,274,000. Bank of America Corp DE bought a new position in Phreesia during the second quarter worth about $6,066,000. Finally, SG Americas Securities LLC raised its stake in Phreesia by 544.3% during the first quarter. SG Americas Securities LLC now owns 457,925 shares of the company’s stock worth $3,837,000 after acquiring an additional 386,848 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc is a healthcare technology company that provides a platform for managing administrative and financial interactions between healthcare organizations and their patients. Its software is designed to help medical practices and other care providers streamline registration, intake, payments, communications and related workflows.

The Phreesia platform includes digital patient check-in tools that allow patients to complete forms, update demographic and insurance information, make payments and review relevant educational or administrative content.